(Q21195369)

English

Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

0 references

Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis (English)

0 references

0 references

0 references

quality of life

1 reference

based on heuristic

inferred from title

ankylosing spondylitis

1 reference

based on heuristic

inferred from title

Dennis A Revicki

2

object named as

Dennis A Revicki

author given names

Dennis A

author last names

Revicki

1 reference

PubMed publication ID

18 August 2022

author name string

Désirée M van der Heijde

1

author given names

Désirée M

author last names

van der Heijde

1 reference

PubMed publication ID

18 August 2022

Katherine L Gooch

3

author given names

Katherine L

author last names

Gooch

1 reference

PubMed publication ID

18 August 2022

Robert L Wong

4

author given names

Robert L

author last names

Wong

1 reference

PubMed publication ID

18 August 2022

Hartmut Kupper

5

author given names

Hartmut

author last names

Kupper

1 reference

PubMed publication ID

18 August 2022

Neesha Harnam

6

author given names

Neesha

author last names

Harnam

1 reference

PubMed publication ID

18 August 2022

Chris Thompson

7

author given names

Chris

author last names

Thompson

1 reference

PubMed publication ID

18 August 2022

Joachim Sieper

8

author given names

Joachim

author last names

Sieper

1 reference

PubMed publication ID

18 August 2022

language of work or name

0 references

publication date

2009

0 references

Arthritis Research and Therapy

0 references

11

0 references

4

0 references

R124

0 references

Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745808

19 March 2017

Six months open label trial of leflunomide in active ankylosing spondylitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745808

19 March 2017

Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745808

19 March 2017

A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745808

19 March 2017

Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745808

12 September 2017

Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745808

12 September 2017

Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745808

12 September 2017

Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745808

12 September 2017

How do the EQ-5D, SF-6D and the well-being rating scale compare in patients with ankylosing spondylitis?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745808

12 September 2017

Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745808

12 September 2017

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745808

12 September 2017

Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745808

12 September 2017

Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745808

12 September 2017

Health status of patients with ankylosing spondylitis: a comparison with the general population

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745808

12 September 2017

Evaluation of the smallest detectable difference in outcome or process variables in ankylosing spondylitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745808

12 September 2017

Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745808

12 September 2017

A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745808

12 September 2017

Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745808

12 September 2017

The epidemiology of ankylosing spondylitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745808

27 September 2017

Disability and handicap in rheumatoid arthritis and ankylosing spondylitis--results from the German rheumatological database. German Collaborative Arthritis Centers.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745808

30 May 2018

Quality of life in patients with ankylosing spondylitis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745808

30 May 2018

Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745808

29 November 2018

Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745808

29 November 2018

Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745808

29 November 2018

Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745808

29 November 2018

Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745808

29 November 2018

Validation exercise of the Ankylosing Spondylitis Assessment Study (ASAS) group response criteria in ankylosing spondylitis patients treated with biologics.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745808

29 November 2018

Functional disability and quality of life in patients with ankylosing spondylitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745808

29 November 2018

Patient centered assessment of ankylosing spondylitis-specific health related quality of life: evaluation of the Patient Generated Index.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745808

29 November 2018

Disease-specific, patient-assessed measures of health outcome in ankylosing spondylitis: reliability, validity and responsiveness.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745808

29 November 2018

Effect sizes for interpreting changes in health status.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745808

29 November 2018

Comparative responsiveness of 3 functional indices in ankylosing spondylitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19686597

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Establishment of the minimum clinically important difference for the bath ankylosing spondylitis indices: a prospective study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19686597

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)

1 reference

https://pubmed.ncbi.nlm.nih.gov/19686597

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19686597

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/19686597

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prospective observational analysis of the efficacy and safety of low-dose (3 mg/kg) infliximab in ankylosing spondylitis: 4-year followup

1 reference

https://pubmed.ncbi.nlm.nih.gov/19686597

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period

1 reference

https://pubmed.ncbi.nlm.nih.gov/19686597

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four-week study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19686597

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Low-dose infliximab treatment for ankylosing spondylitis--clinically- and cost-effective

1 reference

https://pubmed.ncbi.nlm.nih.gov/19686597

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Characteristics and treatment responses of patients satisfying the BSR guidelines for anti-TNF in ankylosing spondylitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19686597

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19686597

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of quality of life using ASQoL questionnaire in patients with ankylosing spondylitis in a Chinese population

1 reference

https://pubmed.ncbi.nlm.nih.gov/19686597

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ankylosing spondylitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19686597

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased efficacy of infliximab associated with methotrexate in ankylosing spondylitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19686597

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PMC publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PubMed publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q21195369&oldid=2175335630"